CRP and myocardial infarction: Inhibition of IL-1β by canakinumab, reduced the rates of nonfatal myocardial infarction, nonfatal stroke, or cardiovascular death compared with placebo in patients with prior myocardial infarction and high sensitivity CRP ≥ 2 mg/L, with consistent effects regardless of DM [104, 105].